LON:CRTX CRISM Therapeutics (CRTX) Share Price, News & Analysis GBX 11.15 +0.15 (+1.36%) As of 11:26 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About CRISM Therapeutics Stock (LON:CRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRISM Therapeutics alerts:Sign Up Key Stats Today's Range 11▼ 1250-Day Range 10.50▼ 13.6552-Week Range 8▼ 25Volume791,871 shsAverage Volume293,866 shsMarket Capitalization£5.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026. For more information please visit: https://www.crismtherapeutics.com Read More Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISM Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRTX Stock News HeadlinesCRISM Therapeutics Upsizes Oversubscribed Retail Offer to Fund Cancer Drug Delivery TrialsMay 28, 2026 | tipranks.comCRISM Therapeutics Raises Funds for Glioblastoma TrialDecember 15, 2025 | tipranks.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.June 4 at 1:00 AM | Porter & Company (Ad)CRISM Therapeutics Launches £100,000 Retail Offer to Fund Clinical TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures £1 Million for Phase 2 Glioblastoma TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures Approval for Phase 2 Glioblastoma TrialSeptember 1, 2025 | tipranks.comCRISM Therapeutics Raises £874,021 to Advance Cancer Treatment TechnologyJuly 3, 2025 | tipranks.comCRISM Director Increases Stake in CompanyApril 7, 2025 | tipranks.comSee More Headlines CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed this year? CRISM Therapeutics' stock was trading at GBX 9 on January 1st, 2026. Since then, CRTX shares have increased by 23.9% and is now trading at GBX 11.15. How were CRISM Therapeutics' earnings last quarter? CRISM Therapeutics Corporation (LON:CRTX) issued its earnings results on Monday, September, 15th. The company reported ($2.80) earnings per share for the quarter. How do I buy shares of CRISM Therapeutics? Shares of CRTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings9/15/2025Today6/04/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorBasic Materials Industry Other Industrial Metals & Mining Sub-IndustryN/A Current SymbolLON:CRTX CIKN/A Webwww.crismtherapeutics.com PhoneN/AFaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£792.20 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-109.55% Return on Assets-26.77% Debt Debt-to-Equity RatioN/A Current Ratio3.65 Quick RatioN/A Sales & Book Value Annual Sales£25 thousand Price / Sales230.74 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 43.03 per share Price / Book0.26Miscellaneous Outstanding Shares51,735,000Free FloatN/AMarket Cap£5.77 million OptionableN/A Beta0.61 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:CRTX) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredJune 4: The day smart money moves (not June 12)Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...Behind the Markets | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredAI breakthrough hidden inside SpaceX exposed on June 11On June 11, SpaceX is hosting a major investor event - and growth investor Louis Navellier believes Elon Musk ...InvestorPlace | SponsoredThe Last Time This Happened… 125 Companies Went BankruptIn the 1870s, railroad stocks made up 81% of all NYSE trades - then 125 companies went bankrupt in a single ye...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
